Innovation for Life

Developing Innovative drugs, Biosimilars, Platforms, and Diagnostic technologies to improve lives.

Advancing Antibody Science

Advancing antibody drugs and biosimilars to address unmet medical needs.

Creating Value for a Healthier Life

Improving patient access through cost-effective, high-quality biosimilars.

PRESTIGE BIOPHARMA

PRESTIGE BIOPHARMA IDC

PRESTIGE BIOLOGICS

7

Beyond technological discovery, expanding access to care for patients around the world

Innovative Drug

Development of First-in-Class therapeutics for unmet diseases

Biosimilar

Prominent Biosimilars pipelines for accelerating market access

Platform Technology

A drug delivery platform that enhances treatment convenience

Diagnostics

Diagnostics for Pancreatic cancer by detecting PAUF

Prestige News

Total 65
Number Thumbnail Title Author Date Votes Views
65 Prestige Biopharma IDC Publishes Preclinical Results for Bispecific Antibody IDC007, Targeting Immunotherapy Side Effects
김** | 2026.07.07 | Votes 0 | Views 163
김** 2026.07.07 0 163
64 Prestige Biopharma Enters Strategic MOU with Charles River , a Global Contract Research Organization
김** | 2026.07.02 | Votes 0 | Views 585
김** 2026.07.02 0 585
63 Prestige Biopharma to Present Clinical Development Strategy for Pancreatic Cancer Candidate at ESMO GI 2026
김** | 2026.06.30 | Votes 0 | Views 742
김** 2026.06.30 0 742
62 Prestige Biopharma to Participate in BIO USA 2026, Targeting Global Market Expansion
김** | 2026.06.16 | Votes 0 | Views 981
김** 2026.06.16 0 981
61 Prestige Biopharma IDC Selected for Ministry of Health and Welfare’s Advanced Biopharma Convergence Talent Development Program
김** | 2026.06.08 | Votes 0 | Views 725
김** 2026.06.08 0 725
60 Prestige Biopharma Outlines Phase 2a Clinical Development Roadmap for Pancreatic Cancer Therapy PBP1510
김** | 2026.06.01 | Votes 0 | Views 915
김** 2026.06.01 0 915
59 Prestige Biopharma Expands Global Collaboration Opportunities for Pancreatic Cancer Therapy at ASCO 2026
김** | 2026.05.26 | Votes 0 | Views 949
김** 2026.05.26 0 949
58 Prestige Biopharma IDC Signs Joint Research Agreement for Antibody Therapeutic Development Targeting Cancer Cachexia
김** | 2026.05.19 | Votes 0 | Views 918
김** 2026.05.19 0 918
57 Prestige BioPharma IDC Successfully Attracts Investment for Co-Development Partner
we******** | 2026.05.13 | Votes 0 | Views 807
we******** 2026.05.13 0 807
56 IDC Expands Asset Value to Over 200 Billion KRW… "Accelerating Commercialization on the Back of Financial Stability"
we******** | 2026.05.11 | Votes 0 | Views 945
we******** 2026.05.11 0 945

Read Prestige news >>